poisar

Stocks · News reference

Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?

Henry Khederian

Shares of Iovance Biotherapeutics are trending Friday morning after a momentum surge pushed the biotech stock to a new 52-week high.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IOVA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Iovance Biotherapeutics to Present at Upcoming Conferences

    Iovance Biotherapeutics announced that senior leadership will present at the Wells Fargo Healthcare Conference (September 10) and H.C. Wainwright Global Investment Conference (September 15). The company reported record Q2 2026 revenue of approximately $99M, with U.S. Amtagvi revenue reaching ~$91M and 66% year-over-year growth. Gross margin improved to 56%, and the FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas.

    IOVA
  2. Delveinsight

    Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

    DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

    PFEGMABKPTIIOVABNTX